Allergy Diagnostics & Therapeutics Market Worth $3.8 Billion By 2024

Standard

Allergy Diagnostics Market: Scope and Methodology

Allergy diagnostics includes products and tests that are used to determine the presence of allergens such as grass, weed, peanuts, milk, or drugs etc. in the samples by determining the presence of antibodies developed by the immune system. The report on global allergy diagnostics market, analyzes the current and future prospects of the market. The report consists of an executive summary that provides information about the products, its segments and sub-segments, market opportunity analysis, along with a market snapshot and comparative analysis by geography, in terms of revenue %, for 2015.

The opportunity presented by the global market was pegged at US$1.3 bn in 2015 and is projected to be worth US$3.8 bn by 2024, expanding at a strong CAGR of 12.8% therein.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5147

A detailed overview of market dynamics, including the drivers, restraints, and opportunities of the allergy diagnostics market, along with porter’s analysis, and value chain analysis, of the global market, has been provided in this report. Market revenue analysis for all the above mentioned segments, and their sub segments has been provided for the forecast period of 2016-2024, considering 2015 as the base year, and 2014 as the historical year, along with compound annual growth rate (CAGR %), for the forecast period of 2016-2024. Market share estimations were based on in-depth analysis and study of products, and their features, prices etc.

This report provides in-depth analysis of the allergy diagnostics market. The stakeholders for this report include companies involved in the manufacturing of products for allergy diagnosis. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the allergy diagnostics market. Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2015.

The research methodology is a combination of primary and secondary research. Primary research includes information collected via e-mails, and telephonic interviews of Key Opinion Leaders (KOL), and forms the bulk of our research. Secondary research includes information collected from various sources, by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.

Allergy Diagnostics Market: Segmentation

Based on products, the global allergy diagnostics market has been segmented into assay kits, consumables and instruments. The instruments considered in the study include blot analyzers, luminometers, mass spectrometers, ELISA analyzers, immunoassay analyzers etc. Based on allergen type, the allergy diagnostics market is segmented into inhaled allergens, food allergens, drug allergens, and others. Based on tests, the allergy diagnostics market is segmented into In-vivo tests and In-vitro tests. Based on end users, the market is segmented as hospitals, diagnostic laboratories, academic research institutes, and others.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further segmented into major countries which include, U.S., Canada, Germany, U.K., France, Italy, Spain, rest of Europe, China, Japan, India, Australia, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, Saudi Arabia, South Africa, and Rest of Middle East & Africa.

Allergy Diagnostics Market: Competitive Landscape

The report also comprises list major players in the market, their SWOT analysis, market share of these players in the Allergy Diagnostics market, key business strategies, product portfolios, and recent developments. Key market players profiled in this report include, Thermo Fischer Scientific, Inc., Quest Diagnostics, Inc., BioMerieux SA, Stallergenes Greer, Omega Diagnostics Group Plc, Siemens Healthineers, and HAL Allergy group, among others.

Browse Full Research Report on Allergy Diagnostics Market:
http://www.transparencymarketresearch.com/allergy-diagnostics-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Worldwide Bovine Respiratory Disease Treatment Market: Valuation to Nearly Double by 2024

Standard

Global Bovine Respiratory Disease Treatment Market: Overview

Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for bovine respiratory disease treatment has increased across the globe.

According to Transparency Market Research, the global bovine respiratory disease treatment market was valued at US$805.9 mn in 2015 and is projected to expand at a CAGR of 7.6% from 2016 to 2024. If the numbers hold true, the market will reach US$1543.9 mn by 2024.

You can download a sample report
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13700

Moreover, according to the World Bank Group (2016), global human population is estimated to be 7.4 billion in 2016 and is growing at a rate of 1.8% per year. Hence, demand for beef has increased due to rising population and increasing disposable income across the world. The rising demand for high quality bovine derived products is influencing the bovine respiratory disease treatment market. Despite of innovations in veterinary medicines and advancement in technology, bovine respiratory disease is the leading cause to impact negatively on both the dairy and beef industries due to calf mortality, additional labor cost and treatment expenses. Moreover, bovine respiratory disease affects adversely on reproductive performance, growth and longevity of cattle. Hence, prevention and treatment of bovine respiratory disease have become important to decrease the impact on animal production and the beef industry. Therefore, the bovine respiratory disease treatment market is anticipated to witness significant growth in terms of revenue during the forecast period.

Global Bovine Respiratory Disease Treatment Market: Segmentation

In terms of treatment type, the bovine respiratory disease treatment market has been categorized into vaccines, antibiotics, NSAIDs, and immunomodulators. Causative agents such as viruses leading to bovine respiratory disease have no direct treatment. Hence, vaccination is the preferred choice of preventive action against the disease. This increase market potential for vaccines. However, virus infected cattle is exposed to bacteria, parasites, and various other factors. Therefore, antibiotics are the preferred choice of treatment for bovine respiratory diseases. Effective treatment and significant demand has increased the scope for antibiotics in the bovine respiratory disease treatment market.

However, according to NCBI report, combination treatment with anti-inflammatory drugs such as NSAIDs has better results over the monotherapy of antibiotics. This has led to increase in usage of NSAIDs in bovine respiratory disease treatment. Bovine respiratory disease is generally treated with several combination therapies. However, growing resistance to antibiotics and drying pipeline has increased demand for novel treatment options for which cattle do not develop resistance, and consequently there is no impact on human life.

Development of newer generation antibiotics for cattle is anticipated to drive the global bovine respiratory disease treatment market during the forecast period. In order to avoid the issue of antibiotics resistance in bovine population, preventive measures such as vaccination and immunomodulators has observed increased global acceptance against the bovine respiratory disease. Hence, preventive treatment is gaining momentum due to growing awareness about the negative impact of antibiotics on human health. This has driven the market for immunomodulators, vitamin injections, and other immunity building products.

In terms of disease type, the market has been segmented into upper respiratory tract infections, diphtheria, and pneumonia (lower respiratory tract infection). Upper respiratory tract infections dominated the global bovine respiratory disease market, accounting for significant share in terms of revenue in 2015. Respiratory infections first affect the upper respiratory tract, which is also the most vulnerable region, followed by other parts of the respiratory tract. Diphtheria accounted for significant share of the bovine respiratory disease treatment market in 2015. Pneumonia (lower respiratory tract infection) accounted for high market share, followed after upper respiratory tract infection in 2015. Hence, early detection of infection is important in bovine respiratory diseases treatment.

In terms of distribution channel, the global bovine respiratory disease treatment market has been segmented into veterinary hospitals, veterinary clinics, private veterinary pharmacies, and veterinary research institutes. Veterinary hospitals dominated the global bovine respiratory disease market in 2015. The segment dominated the market due to factors such as rising population of cattle which increases prevalence of bovine respiratory diseases. The private veterinary pharmacies distribution channel segment is projected to register significant CAGR during the forecast period. The segment is likely to witness strong growth in most of the emerging parts of the world and preference for medicines from private veterinary pharmacies for bovine serum respiratory diseases. However, the veterinary clinics and veterinary research institutes segments are expected to grow steadily as majority of procedures are carried out in veterinary hospitals.

Global Bovine Respiratory Disease Treatment Market: Geographical and Competitive Dynamics

Geographically, the bovine respiratory disease treatment market has been categorized in five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America held the major share of the global bovine respiratory disease treatment market in 2015, where the U.S. dominates the market in terms of revenue. Europe accounted for a significant share of the market in 2015. Changing environmental factors, growing prevalence of causative agents for respiratory disease, increasing demand for quality bovine products, and rising bovine population are the key factors driving the bovine respiratory disease treatment market in Europe. Asia Pacific is the largest producer of bovine livestock. Hence, it presents significant opportunities in the bovine respiratory disease treatment market. India and China are the key markets for bovine respiratory disease treatment, as these have largest livestock population compared to other countries across the globe. Latin America and Middle East & Africa have comparatively smaller markets for bovine respiratory disease treatment. However, Brazil, Mexico, and Argentina are the emerging markets in Latin America due to significant number of livestock population.

Key players operating in the global bovine respiratory disease treatment market are Merck & Co., Inc., Zoetis Services LLC, Bayer AG, Elanco, Merial, Boehringer Ingelheim GmbH, Virbac Group, Ceva, Vetoquinol, and Bimeda Animal Health, among others.

Browse Full Research Report on Bovine Respiratory Disease Treatment Market:
http://www.transparencymarketresearch.com/bovine-respiratory-disease-treatment-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Topical Agents to Remain Most Widely Used Product Type for Treatment of Radiodermatitis Market

Standard

Radiodermatitis Market: Snapshot

The radiodermatitis market exhibits high potential due to untapped needs and is set to grow rapidly in the near future due to a rise in the incidence of cancer and the growing adoption of radiation therapy. An increasing focus on research to find a standard pertinent treatment is also expected to propel the radiodermatitis market. The lack of standard care products in the market makes it a highly opportune condition for players to set their innovative product ideas on the path of commercial success.

The nuances of product usage, effectiveness, and patient comfort are often best understood by oncologists and skin specialists. Hence, partnering with such specialists to bridge the existing need gap is set to be a lucrative opportunity during the forecast period. The global radiodermatitis market was valued at US$299.6 mn in 2015 and is projected to expand at a CAGR of 3.9% from 2016 to 2024 to reach US$421.5 mn by 2024.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2157

Topical Segment Leads Radiodermatitis Market by Product Type

The topical products segment accounted for a significant share in the global radiodermatitis market in 2015. Their ease of availability off-the-shelf as well as their affordability makes topical products a convenient purchase option for all strata of consumers. Topical agents comprise corticosteroid creams, hydrophilic creams, and topical antibiotics. Hydrophilic creams are extensively used across the globe as these provide hydration and relief from itching. These are often the first purchase option at the commencement of symptoms of radiation dermatitis for patients undergoing radiation therapy.

Dressings also form a key segment in the radiodermatitis market in terms of growth. These products are expensive in comparison to topical applicants; however, they present necessary purchase options for patients who have progressed to the RTOG grade 3 or moist desquamation stage post the onset of radiodermatitis. Positive results of academic and clinical research pertaining to the benefits of dressings such as Cavilon no-sting barrier film and Mepitel film have paved the way for these products, which are now prescribed by several institutions. Such research is likely to propel the dressings segment.

Introduction of Favorable Policies Driving Radiodermatitis Market in MEA

TMR states that Asia Pacific is expected to lead the global radiodermatitis market throughout the forecast period. A large population suffering from cancer translates to a higher percentage of patients eligible for radiotherapy and this is expected to drive the market in the region. The population in this region is not yet well acquainted with the practice of routine hygiene-based preventive measures. This augments the chance of developing more severe inflammation compared to people in North America or Europe. Moreover, several countries in Asia Pacific fall in the tropical region, where the severity of radiation dermatitis increases during humid weather conditions.

Global companies are increasingly focusing on emerging economies such as Latin America and the Middle East and Africa as these appear to be bright spots in the global radiodermatitis market. Key attractive features in these regions include a large underserved population, especially in central Africa and the Middle East, and the advent of favorable policies toward the growth of radiotherapy in the region. Moreover, the changing disease profile in the Middle East is resulting in an increased focus on studies pertaining to cancer care in this region.

Europe’s significant share in the radiodermatitis market can be attributed to the high volume of R&D activities in life sciences, superior product launches by companies headquartered in the region, and the rise in academic research in radiation dermatitis. The North America market for radiodermatitis is fueled by the presence of highly renowned pharmaceutical companies, research organizations, and government institutes in the region, which are focused on devising a standard treatment solution.

Key companies in the radiodermatitis market include 3M Health Care, BMG Pharma, Molnlycke Health Care, Smith & Nephew plc, Derma Sciences, Inc., Alliqua Biomedical, Acelity LP, Intermed Pharmaceuticals, and Stratpharma AG.

Browse Full Research Report on Radiodermatitis Market:
http://www.transparencymarketresearch.com/radiodermatitis-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Intravenous Immunoglobulin (IVIG) Market: Rising Patient Pool of Neurological Disorders to Boost Global Consumption of IVIG Products

Standard

Global Intravenous Immunoglobulin (IVIG) Market: Snapshot

The global market for intravenous immunoglobulin (IVIG) products and therapies is heading in a positive direction due to several innovative techniques and advantages it offers to clinicians worldwide. The market is expected to expand at a healthy pace in the near future. Factors that will support market’s growth include technological improvements in the methods used for production and purification of IVIG products and an improving health care infrastructure across the globe. The rising patient pool suffering from immunological and neurological disorders, mounting geriatric population, and rising production of IVIG products are also expected to have a significant positive impact on market’s future growth prospects.

Transparency Market Research estimates that the market will exhibit a healthy 8.5% CAGR over the period between 2016 and 2024. Expanding at this pace, the market, which valued at US$7.23 bn in 2015, is expected to reach US$14.92 bn in 2024.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930

Hospitals to Retain Dominance but Lose Promise to Home Care

In terms of end users of IVIG infusion therapy and products, the global IVIG market is segmented into hospitals, clinics, and home care settings. Of these, the hospitals segment is presently the dominant end user of the intravenous immunoglobulin (IVIG) market. A continuous rise in the number of patients opting for hospitals rather than clinics is the major driver of the hospitals segment. High budgetary expenditure, rising government investment, and better reimbursement policies also augment the number of patients opting hospitals for intravenous immunoglobulin (IVIG) therapies.

IVIG infusion therapy is a time consuming procedure, in which the infusion takes place at a slow rate and lasts for a long period of time. This factor is also expected to increase consumer preference to home care settings for treatment. Although the hospitals segment will continue to lead the global IVIG market, the rising inclination to home care is expected to make home care the most lucrative end-user segment of the intravenous immunoglobulin (IVIG) market over the forecast.

Market in North America to Continue to Remain Highly Lucrative

North America is presently the dominant regional market for intravenous immunoglobulin (IVIG) and is likely to witness significant growth during the forecast period as well. In the U.S., North America’s most lucrative IVIG market, the demand for IVIG infusion therapy is driven by the country’s strong economy, advancements in technology, abundant plasma supply, and rising prevalence of immunological disorders. Other factors ascribable to market growth include the favorable reimbursement policies, high investments in research and development, and increasing geriatric population in the country.

FDA’s approval for payments to plasma donors to encourage plasma donation and boost yield is another major factor driving the IVIG market in the U.S. This has helped the country to not only become self-sufficient in plasma supply, but also a major exporter of plasma derived products globally, consecutively strengthening the North America market.

The IVIG market in Europe is also witnessing strong growth owing to increasing patient pool and geriatric population. Higher acceptance of innovative technologies and launch of new products in the region are also driving the IVIG market. Additionally, the ongoing clinical development of new products is anticipated to boost market growth during the forecast period. Asia Pacific is expected to be a promising market for intravenous immunoglobulin (IVIG) due to developing economies and presence of large underserved patient population. The number of patients suffering from immunological diseases is also high in the region, naturally increasing the demand for intravenous immunoglobulin products and therapies.

Some of the key vendors operating in the highly consolidated global IVIG market are Baxalta Incorporated, Biotest AG, CSL Behring LLC, China Biologic Products, Inc., Grifols S.A., LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, and Sanquin Plasma Products B.V.

Browse Full Research Report on Intravenous Immunoglobulin Market:
http://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Biologics Market Analysis and Forecasts, By Application in 2024

Standard

Global Biologics Market: Snapshot

The global pharmaceutical industry has charted growth at an impressive rate in the past few years owing to a vast increase in research and developmental activities, development and launch of new product varieties, breakthrough progress in treatment options for chronic and rare diseases. A significant rise in big pharmaceutical companies’ operational setups and funds directed towards novel and more effective drug varieties for complex diseases has also been observed across the globe in the past few years. The scenario has led to an increased focus on the development of biologics and a large number of international players are venturing into the global biologics market.

Transparency Market Research estimates that the market will tread along a healthy growth path in the next few years. The market is anticipated to exhibit a CAGR of about 10.9% over the period between 2016 and 2024. If the number holds true, the market is expected to rise to a valuation of US$479, 752 mn by 2024.

Request a PDF Brochure with Report Analysis:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15509

Monoclonal Antibodies to Remain Most Profitable Product Variety

The global biologics market is segmented on the basis of product type into monoclonal antibodies, vaccines, recombinant hormones/vaccines, cell therapy, gene therapy and other products. Monoclonal antibodies segment is anticipated to dominate the market throughout the forecast period; the segment is expected to stand for an annual share of 46% by 2024 and expand at a favorable 11.9% CAGR over the period between 2016 and 2024.

The segments of vaccines and recombinant hormones/proteins are also expected to attractive for manufacturers, although growth of these segments will be relatively stationary over the forecast period. The segment of vaccines will exhibit a slight decline by 2024, chiefly owing to the lower pricing of most vaccines and many key contenders on the verge of going off patent in the developed market. The segment of recombinant hormones/proteins will witness a slight rise in its share in the global market by 2024 owing to sustainable sales in developed and emerging markets.

Vast Growth Opportunities in Asia Pacific to Bring in More Investment

Geographically, the global biologics market is segmented into North America, Europe, Latin America, Asia-Pacific, and Middle East and Africa. North America is presently the dominant regional market, holding a share of over 40% in the global market. The region is expected to continue its dominance in terms of revenue contribution to the global market, expected to account for over 40% by 2024 as well.

However, the biologics market in Asia Pacific is expected to emerge as the most attractive regional market, exhibiting a massive 15.6% CAGR from 2016 through 2024. By the end of the forecast period, the region is expected to replace Europe and become the second most profitable region for biologics.

Owing to the presence of an enormous patient-base and low costs of raw material and manufacturing, an increased number of multi-national pharmaceutical companies are expanding their manufacturing and sales capacities in Asia Pacific. Changes in the regulatory scenario in Asia Pacific are also expected to attract many foreign investors in the Asian markets in the next few years. As a result, the biologics market in Asia Pacific is expected to witness highly positive growth in the next few years.

The highly fragmented global market for biologics features the presence of a large number of international pharmaceutical companies and many domestic players. Some of the key vendors in the market are AstraZeneca, AbbVie Inc., Amgen Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Novartis AG, and Sanofi.

Browse Full Research Report on Biologics Market:
http://www.transparencymarketresearch.com/global-biologics-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Ban on API Imports from China to Boost Heparin Production Market in Europe, predicts TMR

Standard

Europe Heparin Market: Snapshot

Europe is among the major regions contributing to the global heparin market owing to its developed economy and high prevalence of coagulation disorders. According to the Ageing Report published by the European Commission in 2015, the percentage of population aged above 65 years is expected to increase from 21.0% in 2013 to 32.0% in 2060. Aging is directly proportional to the rising incidence of venous thromboembolism (VTE) diseases such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Hence, the demand for heparin in Europe is expected to increase in the next few years. The heparin market in Europe was valued at US$2.2 bn in 2015 and is projected to expand at a CAGR of 5.2% from 2016 to 2024 to reach US$3.5 bn in 2024.

Request a PDF Brochure with Report Analysis:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4815

Heparin Most Widely Used in Hospitals across Europe

Based on end user, the heparin market in Europe has been categorized into hospitals, blood and stem cell banks, and others. Hospitals and clinics widely use heparin as a blood thinner in the treatment of various diseases related to cardiovascular, cancer, and orthopedic. Heparin such as Calcilean, Calciparine, Hepalean, Heparin Leo, and Hepalean-lok are prominently used in hospitals for surgical purposes. The hospitals segment accounted for a major share of the heparin market in Europe as most surgical procedures are often performed in hospitals.

The blood and stem cell banks segment also held a significant share of the market in 2015. Blood and stem cell banks use heparin to collect cord blood and stem cells as heparin promotes the growth of human embryonic stem cells in a defined serum-free medium.

Rapid Growth of Heparin Market Anticipated in Several European Nations

The heparin market in Europe has been segmented on the basis of geography into the following major markets: Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe.

Germany accounted for the leading share in the heparin market in Europe in 2015 and is expected to continue its dominance till 2024. Key attributes to the market growth in Germany encompass burgeoning incidence of VTE among patients, resulting in the increased demand for heparin. Moreover, stringent regulations pertaining to Chinese active pharmaceutical ingredients (APIs) due to adulteration issues have attracted new players to the heparin processing and manufacturing business in Europe. Europe has been known to adhere to strict regulations pertaining to the import of heparin. For instance, in 2013, Germany-based meat company, Tönnies GmbH & Co, acquired Pharma Action, a heparin API manufacturer, and proposed to manufacture 30 metric tons of heparin API. Such developments are expected to augment the heparin market’s growth in Germany.

France, Belgium, and Portugal are anticipated to register the highest growth in the coming years. France also held the second position in the heparin market in Europe in 2015. Heparin consumption during and after surgical procedures such as knee replacement, hip surgery, appendectomy, and breast surgery is higher in France as compared to Italy, Spain, and the U.K. The increased risk of thrombosis among the geriatric population is also expected to drive the market for heparin in France.

Major players in the Europe heparin market include Sanofi SA, Pfizer, Inc., Leo Pharma, Teva Pharmaceutical Industries Ltd, and Dr. Reddy’s Laboratories.

Browse Full Research Report on Heparin Market:
http://www.transparencymarketresearch.com/europe-heparin-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

LATAM Pharmaceutical Products Market Value Share Analysis By Product Type 2024

Standard

LATAM Pharmaceutical Products and CMO Market: Snapshot

Latin America has a fast growing healthcare sector and the pharmaceutical industry in the region is likely to witness steady growth during the forecast period of 2016 to 2024. The growth of the pharmaceutical products and CMO market in LATAM is attributed to high foreign investment, a rising geriatric population, an improving regulatory environment, and an increase in trade agreements with other countries such as the U.S., Canada, Japan, and several countries in Europe.

Most pharmaceutical companies in LATAM are gradually outsourcing manufacturing activities to contract manufacturers in order to achieve cost efficiency, quality, capacity, and time to market. It is also being done to obtain expertise in a particular business category such as API manufacturing and packaging, which is not available in-house. According to Transparency Market Research, the pharmaceutical products and CMO market in Latin America is expected to grow from a value of US$127.9 bn in 2015 and to US$286.2 bn by 2024 at a strong CAGR of 9.3% therein.

Request a PDF Brochure with Report Analysis:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14009

TMR Reports Rising Demand for API and Ingredients in LATAM

Based on product type, the pharmaceutical products and CMO market comprises API and ingredients, finished dosage form, and pharmaceutical packaging.

The finished dosage form segment led the pharmaceutical products market in Latin America, accounting for a share of approximately 85% in 2015. This product form is an integral part of formulation and analytical research, clinical pharmacodynamics, and pharmacokinetics and as a result holds a significant share in the LATAM market. However, the API and ingredients segment is projected to expand at a high growth rate due to rising demand for APIs in the region and establishment of major multinational companies.

On the other hand, the API and ingredients segment dominated the CMO market in Latin America, accounting for a share of approximately 60% in 2015. The increasing demand for cost saving and efficiency is boosting this segment. The finished dosage form segment of the CMO market is expected to expand at a significant CAGR during the forecast period.

Improved Regulatory Scenario Works in Favor of Pharmaceutical Products and CMO Market in Brazil

The pharmaceutical products and CMO market in Latin America has been segmented into major countries: Mexico, Brazil, Argentina, Venezuela, and Rest of Latin America.

Brazil accounted for a significant share in the LATAM pharmaceutical product and CMO market in 2015. Brazil’s dominance has been attributed to excellent geographical location, the development of innovative products, better regulatory scenario, and an accessible pricing structure. The rising income of the consumers and an expanding geriatric population will further boost the demand for medication, driving the pharmaceutical product and CMO market in Brazil.

Mexico was the second leading market for pharmaceutical products and CMO in 2015 due to its close proximity to North America. Rising free trade agreements with major countries in Europe and North America and the growing CMO industry are also expected to fuel the pharmaceutical product and CMO market in Mexico.

The pharmaceutical products market in Argentina is projected to expand at a high CAGR during the forecast period due to government support and the increasing reliability of domestic players. Rest of Latin America, which includes Chile, Colombia, Ecuador, Peru, Paraguay, Uruguay, and Bolivia, is projected to witness the second fastest growth rate during the course of the forecast period. Factors such as a large patient pool and favorable government initiatives aimed at improving access to healthcare facilities are likely to propel the pharmaceutical products and CMO market in Rest of Latin America.

Bayer AG, Novartis AG, Merck & Co., Inc., GSK plc, F. Hofmann La Roche, BASF SE, and Boehringer Ingelheim Group are some of the top players in the pharmaceutical products market in Latin America. Key participants in the CMO market in the region include Pisa Farmacéutica, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, and Inc., Landsteiner Scientific.

Browse Full Research Report on Pharmaceutical Products and CMO Market:
http://www.transparencymarketresearch.com/latin-america-pharmaceutical-products-cmo-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/